Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury
Background: The purpose of this study was to investigate if admission levels of total tau (T-tau) and β-amyloid isoforms 1-40 (Aβ40) and 1-42 (Aβ42) could predict clinical outcome in patients with mild traumatic brain injury (mTBI).Methods: A total of 105 patients with mTBI [Glasgow Coma Scale (GCS)...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2020.00325/full |
id |
doaj-4f5115d1c5cc493f8a0582f12e4e3b2e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Iftakher Hossain Iftakher Hossain Iftakher Hossain Iftakher Hossain Mehrbod Mohammadian Mehrbod Mohammadian Riikka S. K. Takala Riikka S. K. Takala Olli Tenovuo Olli Tenovuo Leire Azurmendi Gil Janek Frantzén Janek Frantzén Mark van Gils Peter J. Hutchinson Ari J. Katila Ari J. Katila Henna-Riikka Maanpää Henna-Riikka Maanpää Henna-Riikka Maanpää David K. Menon Virginia F. Newcombe Jussi Tallus Jussi Tallus Jussi Tallus Kevin Hrusovsky David H. Wilson Jessica Gill Kaj Blennow Kaj Blennow Jean-Charles Sanchez Henrik Zetterberg Henrik Zetterberg Henrik Zetterberg Henrik Zetterberg Jussi P. Posti Jussi P. Posti Jussi P. Posti |
spellingShingle |
Iftakher Hossain Iftakher Hossain Iftakher Hossain Iftakher Hossain Mehrbod Mohammadian Mehrbod Mohammadian Riikka S. K. Takala Riikka S. K. Takala Olli Tenovuo Olli Tenovuo Leire Azurmendi Gil Janek Frantzén Janek Frantzén Mark van Gils Peter J. Hutchinson Ari J. Katila Ari J. Katila Henna-Riikka Maanpää Henna-Riikka Maanpää Henna-Riikka Maanpää David K. Menon Virginia F. Newcombe Jussi Tallus Jussi Tallus Jussi Tallus Kevin Hrusovsky David H. Wilson Jessica Gill Kaj Blennow Kaj Blennow Jean-Charles Sanchez Henrik Zetterberg Henrik Zetterberg Henrik Zetterberg Henrik Zetterberg Jussi P. Posti Jussi P. Posti Jussi P. Posti Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury Frontiers in Neurology traumatic brain injury total tau β-amyloid 1-40 β-amyloid 1-42 outcome |
author_facet |
Iftakher Hossain Iftakher Hossain Iftakher Hossain Iftakher Hossain Mehrbod Mohammadian Mehrbod Mohammadian Riikka S. K. Takala Riikka S. K. Takala Olli Tenovuo Olli Tenovuo Leire Azurmendi Gil Janek Frantzén Janek Frantzén Mark van Gils Peter J. Hutchinson Ari J. Katila Ari J. Katila Henna-Riikka Maanpää Henna-Riikka Maanpää Henna-Riikka Maanpää David K. Menon Virginia F. Newcombe Jussi Tallus Jussi Tallus Jussi Tallus Kevin Hrusovsky David H. Wilson Jessica Gill Kaj Blennow Kaj Blennow Jean-Charles Sanchez Henrik Zetterberg Henrik Zetterberg Henrik Zetterberg Henrik Zetterberg Jussi P. Posti Jussi P. Posti Jussi P. Posti |
author_sort |
Iftakher Hossain |
title |
Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury |
title_short |
Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury |
title_full |
Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury |
title_fullStr |
Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury |
title_full_unstemmed |
Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury |
title_sort |
admission levels of total tau and β-amyloid isoforms 1–40 and 1–42 in predicting the outcome of mild traumatic brain injury |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2020-05-01 |
description |
Background: The purpose of this study was to investigate if admission levels of total tau (T-tau) and β-amyloid isoforms 1-40 (Aβ40) and 1-42 (Aβ42) could predict clinical outcome in patients with mild traumatic brain injury (mTBI).Methods: A total of 105 patients with mTBI [Glasgow Coma Scale (GCS) ≥ 13] recruited in Turku University Hospital, Turku, Finland were included in this study. Blood samples were drawn within 24 h of admission for analysis of plasma T-tau, Aβ40, and Aβ42. Patients were divided into computed tomography (CT)-positive and CT-negative groups. The outcome was assessed 6–12 months after the injury using the Extended Glasgow Outcome Scale (GOSE). Outcomes were defined as complete (GOSE 8) or incomplete (GOSE < 8) recovery. The Rivermead Post Concussion Symptoms Questionnaire (RPCSQ) was also used to assess mTBI-related symptoms. Predictive values of the biomarkers were analyzed independently, in panels and together with clinical parameters.Results: The admission levels of plasma T-tau, Aβ40, and Aβ42 were not significantly different between patients with complete and incomplete recovery. The levels of T-tau, Aβ40, and Aβ42 could poorly predict complete recovery, with areas under the receiver operating characteristic curve 0.56, 0.52, and 0.54, respectively. For the whole cohort, there was a significant negative correlation between the levels of T-tau and ordinal GOSE score (Spearman ρ = −0.231, p = 0.018). In a multivariate logistic regression model including age, GCS, duration of posttraumatic amnesia, Injury Severity Score (ISS), time from injury to sampling, and CT findings, none of the biomarkers could predict complete recovery independently or together with the other two biomarkers. Plasma levels of T-tau, Aβ40, and Aβ42 did not significantly differ between the outcome groups either within the CT-positive or CT-negative subgroups. Levels of Aβ40 and Aβ42 did not significantly correlate with outcome, but in the CT-positive subgroup, the levels of T-tau significantly correlated with ordinal GOSE score (Spearman ρ = −0.288, p = 0.035). The levels of T-tau, Aβ40, and Aβ42 were not correlated with the RPCSQ scores.Conclusions: The early levels of T-tau are correlated with the outcome in patients with mTBI, but none of the biomarkers either alone or in any combinations could predict complete recovery in patients with mTBI. |
topic |
traumatic brain injury total tau β-amyloid 1-40 β-amyloid 1-42 outcome |
url |
https://www.frontiersin.org/article/10.3389/fneur.2020.00325/full |
work_keys_str_mv |
AT iftakherhossain admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT iftakherhossain admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT iftakherhossain admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT iftakherhossain admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT mehrbodmohammadian admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT mehrbodmohammadian admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT riikkasktakala admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT riikkasktakala admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT ollitenovuo admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT ollitenovuo admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT leireazurmendigil admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT janekfrantzen admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT janekfrantzen admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT markvangils admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT peterjhutchinson admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT arijkatila admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT arijkatila admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT hennariikkamaanpaa admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT hennariikkamaanpaa admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT hennariikkamaanpaa admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT davidkmenon admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT virginiafnewcombe admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT jussitallus admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT jussitallus admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT jussitallus admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT kevinhrusovsky admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT davidhwilson admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT jessicagill admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT kajblennow admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT kajblennow admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT jeancharlessanchez admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT henrikzetterberg admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT henrikzetterberg admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT henrikzetterberg admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT henrikzetterberg admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT jussipposti admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT jussipposti admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury AT jussipposti admissionlevelsoftotaltauandbamyloidisoforms140and142inpredictingtheoutcomeofmildtraumaticbraininjury |
_version_ |
1724679591569653760 |
spelling |
doaj-4f5115d1c5cc493f8a0582f12e4e3b2e2020-11-25T03:04:50ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-05-011110.3389/fneur.2020.00325521236Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain InjuryIftakher Hossain0Iftakher Hossain1Iftakher Hossain2Iftakher Hossain3Mehrbod Mohammadian4Mehrbod Mohammadian5Riikka S. K. Takala6Riikka S. K. Takala7Olli Tenovuo8Olli Tenovuo9Leire Azurmendi Gil10Janek Frantzén11Janek Frantzén12Mark van Gils13Peter J. Hutchinson14Ari J. Katila15Ari J. Katila16Henna-Riikka Maanpää17Henna-Riikka Maanpää18Henna-Riikka Maanpää19David K. Menon20Virginia F. Newcombe21Jussi Tallus22Jussi Tallus23Jussi Tallus24Kevin Hrusovsky25David H. Wilson26Jessica Gill27Kaj Blennow28Kaj Blennow29Jean-Charles Sanchez30Henrik Zetterberg31Henrik Zetterberg32Henrik Zetterberg33Henrik Zetterberg34Jussi P. Posti35Jussi P. Posti36Jussi P. Posti37Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital, Turku, FinlandTurku Brain Injury Centre, Turku University Hospital, Turku, FinlandDepartment of Clinical Neurosciences, University of Turku, Turku, FinlandDepartment of Clinical Neurosciences, Neurosurgery Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, United KingdomTurku Brain Injury Centre, Turku University Hospital, Turku, FinlandDepartment of Clinical Neurosciences, University of Turku, Turku, FinlandPerioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital, Turku, FinlandAnaesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku, Turku, FinlandTurku Brain Injury Centre, Turku University Hospital, Turku, FinlandDepartment of Clinical Neurosciences, University of Turku, Turku, FinlandDepartment of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandDivision of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital, Turku, FinlandDepartment of Clinical Neurosciences, University of Turku, Turku, FinlandVTT Technical Research Centre of Finland Ltd., Tampere, FinlandDepartment of Clinical Neurosciences, Neurosurgery Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, United KingdomPerioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital, Turku, FinlandAnaesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku, Turku, FinlandDivision of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital, Turku, FinlandTurku Brain Injury Centre, Turku University Hospital, Turku, FinlandDepartment of Clinical Neurosciences, University of Turku, Turku, FinlandDivision of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, United KingdomDivision of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, United KingdomTurku Brain Injury Centre, Turku University Hospital, Turku, FinlandDepartment of Clinical Neurosciences, University of Turku, Turku, Finland0Department of Radiology, Turku University Hospital, Turku, Finland1Quanterix Corporation, Lexington, MA, United States1Quanterix Corporation, Lexington, MA, United States2National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, United States3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden4Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, SwedenDepartment of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden4Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden5Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom6UK Dementia Research Institute at UCL, University College London, London, United KingdomDivision of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital, Turku, FinlandTurku Brain Injury Centre, Turku University Hospital, Turku, FinlandDepartment of Clinical Neurosciences, University of Turku, Turku, FinlandBackground: The purpose of this study was to investigate if admission levels of total tau (T-tau) and β-amyloid isoforms 1-40 (Aβ40) and 1-42 (Aβ42) could predict clinical outcome in patients with mild traumatic brain injury (mTBI).Methods: A total of 105 patients with mTBI [Glasgow Coma Scale (GCS) ≥ 13] recruited in Turku University Hospital, Turku, Finland were included in this study. Blood samples were drawn within 24 h of admission for analysis of plasma T-tau, Aβ40, and Aβ42. Patients were divided into computed tomography (CT)-positive and CT-negative groups. The outcome was assessed 6–12 months after the injury using the Extended Glasgow Outcome Scale (GOSE). Outcomes were defined as complete (GOSE 8) or incomplete (GOSE < 8) recovery. The Rivermead Post Concussion Symptoms Questionnaire (RPCSQ) was also used to assess mTBI-related symptoms. Predictive values of the biomarkers were analyzed independently, in panels and together with clinical parameters.Results: The admission levels of plasma T-tau, Aβ40, and Aβ42 were not significantly different between patients with complete and incomplete recovery. The levels of T-tau, Aβ40, and Aβ42 could poorly predict complete recovery, with areas under the receiver operating characteristic curve 0.56, 0.52, and 0.54, respectively. For the whole cohort, there was a significant negative correlation between the levels of T-tau and ordinal GOSE score (Spearman ρ = −0.231, p = 0.018). In a multivariate logistic regression model including age, GCS, duration of posttraumatic amnesia, Injury Severity Score (ISS), time from injury to sampling, and CT findings, none of the biomarkers could predict complete recovery independently or together with the other two biomarkers. Plasma levels of T-tau, Aβ40, and Aβ42 did not significantly differ between the outcome groups either within the CT-positive or CT-negative subgroups. Levels of Aβ40 and Aβ42 did not significantly correlate with outcome, but in the CT-positive subgroup, the levels of T-tau significantly correlated with ordinal GOSE score (Spearman ρ = −0.288, p = 0.035). The levels of T-tau, Aβ40, and Aβ42 were not correlated with the RPCSQ scores.Conclusions: The early levels of T-tau are correlated with the outcome in patients with mTBI, but none of the biomarkers either alone or in any combinations could predict complete recovery in patients with mTBI.https://www.frontiersin.org/article/10.3389/fneur.2020.00325/fulltraumatic brain injurytotal tauβ-amyloid 1-40β-amyloid 1-42outcome |